The initiative, called the Diabetes Hothouse, is the first to arise from the NHS England and ABPI Priority Delivery Agreement, which was launched earlier this year and seeks to facilitate faster access of new, evidenced-based technology for patients.
The Diabetes Hothouse is calling for innovators to take part in the programme and said that successful innovations will receive support in either funding or clinical expertise, so they can spread their solutions across the country.
It said that the digital innovations might be either novel uses of existing technologies or new innovations, and could include software, apps, hybrid technology-service and device-software that support pathway improvement, better diagnosis, or improved management in line with the tailored needs of the patient. In addition, they must also support existing national diabetes priorities so that patients receive the right care at the right time. These are: improving hospital safety; reducing amputation rates; improving the three treatment targets, aligned to early intervention; maternal health; and mental health.
“Technology is really improving our daily lives and the NHS wants to use its power to improve the lives of patients living with both Type 1 and Type 2 diabetes and women with diabetes. This is a call out for the very best innovations in healthcare which will help NHS patients manage their conditions and, as we look to the future of the NHS, the long-term plan will continue to champion world leading technology to improve patient care,” said Dr Partha Kar, Associate National Clinical Director for Diabetes, NHS England.
Colette Goldrick, Director of NHS Engagement at the ABPI, said: “It’s great to see the first initiative under the Diabetes Priority agreement between ABPI and NHS England coming to life, and even better to have on board the added expertise of our partners in the AHSN Network. I’m sure that the Diabetes Hothouse process will surface some valuable digital innovations that ABPI members can support to create a triple win – better outcomes for people with diabetes, better use of resources for the NHS, and a positive signal of rapid uptake and spread for the life sciences industry.”